U.S. markets open in 3 hours 48 minutes
  • S&P Futures

    4,017.50
    -15.00 (-0.37%)
     
  • Dow Futures

    33,680.00
    -105.00 (-0.31%)
     
  • Nasdaq Futures

    11,901.75
    -66.25 (-0.55%)
     
  • Russell 2000 Futures

    1,887.70
    -5.80 (-0.31%)
     
  • Crude Oil

    76.76
    -1.14 (-1.46%)
     
  • Gold

    1,904.40
    -18.50 (-0.96%)
     
  • Silver

    23.21
    -0.52 (-2.20%)
     
  • EUR/USD

    1.0828
    -0.0028 (-0.26%)
     
  • 10-Yr Bond

    3.5510
    0.0000 (0.00%)
     
  • Vix

    20.53
    +2.02 (+10.91%)
     
  • GBP/USD

    1.2318
    -0.0035 (-0.29%)
     
  • USD/JPY

    130.3800
    +0.0220 (+0.02%)
     
  • BTC-USD

    22,890.17
    -391.42 (-1.68%)
     
  • CMC Crypto 200

    519.11
    -18.76 (-3.49%)
     
  • FTSE 100

    7,730.72
    -54.15 (-0.70%)
     
  • Nikkei 225

    27,327.11
    -106.29 (-0.39%)
     

Albireo Pharma (NASDAQ:ALBO) dips 16% this week as increasing losses might not be inspiring confidence among its investors

The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. For example, the Albireo Pharma, Inc. (NASDAQ:ALBO) share price is down 34% in the last year. That falls noticeably short of the market decline of around 24%. On the bright side, the stock is actually up 1.8% in the last three years. Furthermore, it's down 17% in about a quarter. That's not much fun for holders. However, one could argue that the price has been influenced by the general market, which is down 8.7% in the same timeframe.

Since Albireo Pharma has shed US$75m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

Check out our latest analysis for Albireo Pharma

Because Albireo Pharma made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Albireo Pharma grew its revenue by 433% over the last year. That's a strong result which is better than most other loss making companies. The share price drop of 34% over twelve months would be considered disappointing by many, so you might argue the company is getting little credit for its impressive revenue growth. On the bright side, if this company is moving profits in the right direction, top-line growth like that could be an opportunity. Our brains have evolved to think in linear fashion, so there's value in learning to recognize exponential growth. We are, in some ways, simply the wisest of the monkeys.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

While the broader market lost about 24% in the twelve months, Albireo Pharma shareholders did even worse, losing 34%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 3% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 3 warning signs for Albireo Pharma you should know about.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here